Study wrapper · #1338
Late-life semaglutide treatment slows ageing and extends lifespan in female mice.
Editor's note
This is the strongest published case so far that GLP-1 receptor activation behaves as a calorie-restriction mimetic, with lifespan extension and modulation of conserved genetic regulators of ageing. The design is what gives it weight: dosing began late in life, and matched calorie restriction ran as a live comparator rather than a citation. The usual limits apply, since this is one mouse strain, female animals only, and no human lifespan data exists. Its main value is a mechanistic frame for the pleiotropic effects clinicians keep reporting.
Plain-language abstract
Female mice given semaglutide starting at 20 months old, roughly late middle age, held onto physical and cognitive function better than control animals and went on to live longer. The effects closely resembled calorie restriction, and on exploratory drive, spatial memory and glucose control the drug did somewhat better than calorie restriction itself.